In addition, as with other research, our study showed that patients with non-stricturing and non-penetrating diseases (Montreal Classification B1) tended to have a more beneficial response to anti-TNF agents than stenosing disease (B2) or fistulizing disease (B3) [8, 46, 47]. The gene discussed is TNF; the disease is glycogen storage disease VI.